What is Jazz Pharmaceuticals's R&D?

Jazz Pharmaceuticals (JAZZ) reported R&D of $196M in Q1 2026.

How has Jazz Pharmaceuticals's R&D changed year-over-year?

Jazz Pharmaceuticals's R&D increased by 8.5% year-over-year, from $180.7M to $196M.

Money spent on creating and testing new drugs.

How do you interpret R&D?

Higher spending is essential for long-term growth in biopharma, though it reduces short-term profitability.

How does R&D compare across companies?

Key performance indicator for all innovation-driven biopharmaceutical firms.

Jazz Pharmaceuticals JAZZ R&D

R&D at other companies

AmgenAMGN

$1.72B+15.7%

BridgeBio PharmaBBIO

$126.64M+13.6%

Ionis PharmaceuticalsIONS

$228.9M+1.6%

BiogenBIIB

$539M+24.2%

Bristol-Myers SquibbBMY

$2.65B+17.4%

Neurocrine BiosciencesNBIX

$296.2M+12.5%

Other financials

Income statement

See full

Revenue$1.1B+19.1%

Operating income$336.6M+702%

Net income$293.1M+417%

EPS (diluted)$4.43+391%

Balance sheet

See full

Cash & equivalents$667.5M-64.1%

Total debt$5.4B-0.1%

Total equity$4.5B+8.6%

Total assets$11.9B+2.8%

Cash flow

See full

Operating cash flow$408.2M-5.0%

CapEx$19.7M+41.7%

Free cash flow$388.5M-6.6%

Valuation

See full

Market cap$14.11B+54.4%

Enterprise value$18.85B+47.7%

P/S3.2×+0.9×

Profitability

See full

Operating margin-11.9%-28.1pp

Net margin-8.9%-20.5pp

FCF margin28.6%-8.6pp

Returns & leverage

See full

Return on equity-9.1%-21.2pp

Debt / equity1.2×-0.1×

Current ratio2×-1.3×

Where this comes from

Reported directly by Jazz Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost.

The official record: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Jazz Pharmaceuticals's r&d.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Jazz Pharmaceuticals's R&D?: Jazz Pharmaceuticals (JAZZ) reported R&D of $196M in Q1 2026.
How has Jazz Pharmaceuticals's R&D changed year-over-year?: Jazz Pharmaceuticals's R&D increased by 8.5% year-over-year, from $180.7M to $196M.
What does R&D mean?: Money spent on creating and testing new drugs.
How do you interpret R&D?: Higher spending is essential for long-term growth in biopharma, though it reduces short-term profitability.
How does R&D compare across companies?: Key performance indicator for all innovation-driven biopharmaceutical firms.